Get the Stockscreener App
5.1786
1.73%
-0.0914
After Hours:
5.18
0.0014
+0.03%
Bolt Biotherapeutics Inc stock is traded at $5.1786, with a volume of 3,723.
It is down -1.73% in the last 24 hours and down -5.84% over the past month.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
See More
Previous Close:
$5.27
Open:
$5.255
24h Volume:
3,723
Relative Volume:
0.21
Market Cap:
$9.94M
Revenue:
$7.88M
Net Income/Loss:
$-69.20M
P/E Ratio:
-2.8298
EPS:
-1.83
Net Cash Flow:
$-69.73M
1W Performance:
-0.22%
1M Performance:
-5.84%
6M Performance:
-35.72%
1Y Performance:
-58.11%
1-Day Range:
$5.17
$5.32
1-Week Range:
$4.9946
$5.50
52-Week Range:
$4.59
$14.36
Bolt Biotherapeutics Inc Stock (BOLT) Company Profile
Name
Bolt Biotherapeutics Inc
Sector
Industry
Phone
650-665-9295
Address
900 CHESAPEAKE DRIVE, REDWOOD CITY
Compare BOLT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BOLT
Bolt Biotherapeutics Inc
|
5.1786 | 10.11M | 7.88M | -69.20M | -69.73M | -1.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Bolt Biotherapeutics Inc Stock (BOLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-02-21 | Initiated | Guggenheim | Buy |
| Mar-02-21 | Initiated | Morgan Stanley | Overweight |
| Mar-02-21 | Initiated | SVB Leerink | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
Bolt Biotherapeutics Inc Stock (BOLT) Latest News
What Fibonacci levels say about Bolt Biotherapeutics Inc. reboundEarnings Recap Report & Weekly Top Gainers Alerts - Newser
How to track smart money flows in Bolt Biotherapeutics Inc.Market Performance Report & Real-Time Market Sentiment Alerts - Newser
Is a relief rally coming for Bolt Biotherapeutics Inc. holdersJuly 2025 Patterns & Fast Entry High Yield Tips - Newser
How hedge fund analytics apply to Bolt Biotherapeutics Inc. stockWeekly Trade Review & Daily Oversold Stock Bounce Ideas - Newser
Price momentum metrics for Bolt Biotherapeutics Inc. explainedJuly 2025 Levels & Reliable Breakout Forecasts - Newser
Bolt Biotherapeutics Inc. stock momentum explained2025 Sector Review & Safe Entry Zone Tips - Newser
What data driven models say about Bolt Biotherapeutics Inc.’s futureBreakout Watch & High Return Trade Guides - Newser
Why Bolt Biotherapeutics Inc. is moving todayJuly 2025 PostEarnings & Long Hold Capital Preservation Tips - Newser
Combining price and volume data for Bolt Biotherapeutics Inc.Market Sentiment Review & Weekly High Return Stock Forecasts - Newser
Price action breakdown for Bolt Biotherapeutics Inc.Weekly Profit Analysis & AI Enhanced Trading Alerts - Newser
Quantitative breakdown of Bolt Biotherapeutics Inc. recent moveJuly 2025 Retail & Daily Stock Trend Reports - Newser
Using data models to predict Bolt Biotherapeutics Inc. stock movementWeekly Stock Recap & Real-Time Volume Analysis - Newser
Can a trend reversal in Bolt Biotherapeutics Inc. lead to recoveryJuly 2025 Decliners & Reliable Volume Spike Trade Alerts - Newser
What’s the recovery path for long term holders of Bolt Biotherapeutics Inc.Take Profit & Weekly High Potential Alerts - Newser
Using data filters to optimize entry into Bolt Biotherapeutics Inc.Swing Trade & Free Risk Controlled Daily Trade Plans - Newser
What recovery options are there for Bolt Biotherapeutics Inc.Quarterly Earnings Report & Low Risk High Reward Trade Ideas - Newser
What to expect from Bolt Biotherapeutics Inc. in the next 30 daysWeekly Risk Report & Weekly Stock Performance Updates - Newser
Should you hold or exit Bolt Biotherapeutics Inc. nowMarket Movement Recap & Consistent Profit Trade Alerts - Newser
Is Bolt Biotherapeutics Inc. trending in predictive chart models2025 Stock Rankings & Long-Term Investment Growth Plans - Newser
Can machine learning forecast Bolt Biotherapeutics Inc. recoveryJuly 2025 WrapUp & Weekly Sector Rotation Insights - Newser
Quarterly Trades: Is Bolt Biotherapeutics Inc. benefiting from innovation trendsJuly 2025 Earnings & Detailed Earnings Play Alerts - Lancaster City Council
Understanding Bolt Biotherapeutics Inc.’s price movementMarket Performance Recap & Low Drawdown Investment Ideas - Newser
How to use a screener to detect Bolt Biotherapeutics Inc. breakoutsMarket Performance Summary & Weekly Breakout Stock Alerts - Newser
Resistance Break Could Fuel Bolt Biotherapeutics Inc. RallyEarnings Risk Summary & Weekly Stock Performance Updates - beatles.ru
Intraday pattern recognizer results for Bolt Biotherapeutics Inc.July 2025 Retail & Smart Allocation Stock Tips - Newser
Bolt Biotherapeutics Inc Stock (BOLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):